Tamoxifen dosing for Cre-mediated recombination in experimental bronchopulmonary dysplasia.

Ruiz-Camp J, Rodr?guez-Castillo JA, Herold S, Mayer K, Vad?sz I, Tallquist MD, Seeger W, Ahlbrecht K, Morty RE. Tamoxifen dosing for Cre-mediated recombination in experimental bronchopulmonary dysplasia. Transgenic Res. 2017 02; 26(1):165-170.

View in: PubMed

subject areas

Animals
Bronchopulmonary Dysplasia
Disease Models, Animal
Humans
Hyperoxia
Integrases
Lung
Mice, Transgenic
Oxygen Consumption
Premature Birth
Recombination, Genetic
Tamoxifen

authors with profiles

Michelle Tallquist, PHD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support